|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM277644402 |
| 003 |
DE-627 |
| 005 |
20231225014712.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2017.10.013
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0925.xml
|
| 035 |
|
|
|a (DE-627)NLM277644402
|
| 035 |
|
|
|a (NLM)29097196
|
| 035 |
|
|
|a (PII)S1521-6616(17)30214-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kaartinen, Kati
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.03.2019
|
| 500 |
|
|
|a Date Revised 18.03.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2017 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a There is a great lack of efficient treatments for membranoproliferative glomerulonephritis (MPGN) and recently emerged complement therapies have been proposed to be useful. We report a patient with a complement-mediated MPGN having recurrencies in kidney allografts and an unsuccessful treatment with complement inhibitor, eculizumab (anti-C5 monoclonal antibody). Nephritic factor (C3Nef), an autoantibody against C3bBb, in the patient serum activated C3 but not C5 showing that major damage was mediated by C3 activation with clearly less involvement of C5 explaining unresponsiveness to eculizumab. Analyzing C3Nef-mediated C3 and C5 activation separately could help in choosing the right patients for eculizumab therapy
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a C3 glomerulonephritis
|
| 650 |
|
4 |
|a C3 nephritic factor
|
| 650 |
|
4 |
|a Eculizumab
|
| 650 |
|
4 |
|a Transplantation
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Complement C3 Nephritic Factor
|2 NLM
|
| 650 |
|
7 |
|a Complement Inactivating Agents
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a eculizumab
|2 NLM
|
| 650 |
|
7 |
|a A3ULP0F556
|2 NLM
|
| 700 |
1 |
|
|a Martola, Leena
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Räisänen-Sokolowski, Anne
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meri, Seppo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 187(2018) vom: 01. Feb., Seite 104-106
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:187
|g year:2018
|g day:01
|g month:02
|g pages:104-106
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2017.10.013
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 187
|j 2018
|b 01
|c 02
|h 104-106
|